Samsung BioLogics IPO May Set Tone For Korean Biopharma Investors

Samsung BioLogics has set out plans for one of the biggest ever IPOs in South Korea that could help reignite investor sentiment battered by recent events surrounding Hanmi.

Samsung BioLogics plans to raise up to KRW2.25tn ($2bn) in an initial public offering in South Korea's benchmark stock market in November to support investment in new production facilities and subsidiaries, as well as to pay back loans.

During the planned Nov. 2-3 IPO, the Samsung Group affiliate will offer 16,541,302 shares on the main KOSPI market, of...

More from South Korea

More from Focus On Asia